The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Adenosine Metabolism: Emerging Concepts for Cancer Therapy
Open accessAbstract
Summary Adenosine is a key metabolic and immune checkpoint regulator implicated in the tumor escape from the host immune system. Major gaps in knowledge that impede the development of effective adenosine-based therapeutics include: (1) Lack of consideration of redundant pathways controlling ATP and adenosine levels; (2) lack of distinction between receptor-dependent and - independent effects of adenosine, and (3) focus on extracellular adenosine without consideration of intracellular metabolism and compartmentalization. In light of current clinical trials, we provide an overview of adenosine metabolism and point out the need for a more careful evaluation of the entire purinome in emerging cancer therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Receptors for Purines and Pyrimidines
Burnstock, G., & Verkhratsky, A. (2012) · Purinergic Signalling and the Nervous System · doi:10.1007/978-3-642-28863-0_5 · Cited by 3,958
On Respiratory Impairment in Cancer Cells
Warburg, O. (1956) · Science · doi:10.1126/science.124.3215.269 · Cited by 3,468
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053
Cancer metabolism: a therapeutic perspective
Martinez-Outschoorn, U. E., Peiris-Pagés, M., Pestell, R. G., Sotgia, F., & Lisanti, M. P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.60 · Cited by 1,505
Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Michaud, M., Martins, I., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Pellegatti, P., Shen, S., Kepp, O., Scoazec, M., Mignot, G., et al. (2011) · Science · doi:10.1126/science.1208347 · Cited by 1,377
Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates
Simoni, Y., Becht, E., Fehlings, M., Loh, C. Y., Koo, S.-L., Teng, K. W. W., Yeong, J. P. S., Nahar, R., Zhang, T., Kared, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0130-2 · Cited by 1,370
Ohta, A., & Sitkovsky, M. (2001) · Nature · doi:10.1038/414916a · Cited by 1,334
Combination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
Yegutkin, G. G. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.01.024 · Cited by 1,154
Self-citationA2A adenosine receptor protects tumors from antitumor T cells
Ohta, A., Gorelik, E., Prasad, S. J., Ronchese, F., Lukashev, D., Wong, M. K. K., Huang, X., Caldwell, S., Liu, K., Smith, P., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605251103 · Cited by 1,065
Bours, M. J. L., Swennen, E. L. R., Di Virgilio, F., Cronstein, B. N., & Dagnelie, P. C. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.04.013 · Cited by 1,030
DNA methylation pathways and their crosstalk with histone methylation
Du, J., Johnson, L. M., Jacobsen, S. E., & Patel, D. J. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4043 · Cited by 1,000
Cellular function and molecular structure of ecto-nucleotidases
Zimmermann, H., Zebisch, M., & Sträter, N. (2012) · Purinergic Signalling · doi:10.1007/s11302-012-9309-4 · Cited by 977
The ectonucleotidases CD 39 and CD 73: Novel checkpoint inhibitor targets
Allard, B., Longhi, M. S., Robson, S. C., & Stagg, J. (2017) · Immunological Reviews · doi:10.1111/imr.12528 · Cited by 927
Adenosine receptors as drug targets — what are the challenges?
Chen, J.-F., Eltzschig, H. K., & Fredholm, B. B. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3955 · Cited by 895
Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence
Rajman, L., Chwalek, K., & Sinclair, D. A. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.02.011 · Cited by 865
Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology
Malavasi, F., Deaglio, S., Funaro, A., Ferrero, E., Horenstein, A. L., Ortolan, E., Vaisitti, T., & Aydin, S. (2008) · Physiological Reviews · doi:10.1152/physrev.00035.2007 · Cited by 862
Targeting immunosuppressive adenosine in cancer
Vijayan, D., Young, A., Teng, M. W. L., & Smyth, M. J. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.86 · Cited by 840
Immunity, inflammation and cancer: a leading role for adenosine
Antonioli, L., Blandizzi, C., Pacher, P., & Haskó, G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3613 · Cited by 765
Maj, T., Wang, W., Crespo, J., Zhang, H., Wang, W., Wei, S., Zhao, L., Vatan, L., Shao, I., Szeliga, W., et al. (2017) · Nature Immunology · doi:10.1038/ni.3868 · Cited by 733
Extracellular ATP and P2 purinergic signalling in the tumour microenvironment
Di Virgilio, F., Sarti, A. C., Falzoni, S., De Marchi, E., & Adinolfi, E. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0037-0 · Cited by 723
Purinergic Signaling during Inflammation
Eltzschig, H. K., Sitkovsky, M. V., & Robson, S. C. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1205750 · Cited by 706
Purinergic Signaling during Inflammation
(2013) · New England Journal of Medicine · doi:10.1056/nejmc1300259 · Cited by 608
Targeting adenosine for cancer immunotherapy
Leone, R. D., & Emens, L. A. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0360-8 · Cited by 543
Turnover of adenosine in plasma of human and dog blood
Moser, G. H., Schrader, J., & Deussen, A. (1989) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1989.256.4.c799 · Cited by 529
CD38 antibodies in multiple myeloma: back to the future
van de Donk, N. W. C. J., Richardson, P. G., & Malavasi, F. (2018) · Blood · doi:10.1182/blood-2017-06-740944 · Cited by 493
Syn, N., Wang, L., Sethi, G., Thiery, J.-P., & Goh, B.-C. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.04.006 · Cited by 478
Cancer as a metabolic disease: implications for novel therapeutics
Seyfried, T. N., Flores, R. E., Poff, A. M., & D'Agostino, D. P. (2014) · Carcinogenesis · doi:10.1093/carcin/bgt480 · Cited by 472
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade
Chen, L., Diao, L., Yang, Y., Yi, X., Rodriguez, B. L., Li, Y., Villalobos, P. A., Cascone, T., Liu, X., Tan, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1033 · Cited by 462
(1997) · PubMed · Cited by 433
Perrot, I., Michaud, H.-A., Giraudon-Paoli, M., Augier, S., Docquier, A., Gros, L., Courtois, R., Déjou, C., Jecko, D., Becquart, O., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.04.091 · Cited by 423
Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
Vigano, S., Alatzoglou, D., Irving, M., Ménétrier-Caux, C., Caux, C., Romero, P., & Coukos, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00925 · Cited by 420
Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses
Young, A., Ngiow, S. F., Barkauskas, D. S., Sult, E., Hay, C., Blake, S. J., Huang, Q., Liu, J., Takeda, K., Teng, M. W. L., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.025 · Cited by 388
Purine Release, Metabolism, and Signaling in the Inflammatory Response
Linden, J., Koch-Nolte, F., & Dahl, G. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052406 · Cited by 377
Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy
Beavis, P. A., Henderson, M. A., Giuffrida, L., Mills, J. K., Sek, K., Cross, R. S., Davenport, A. J., John, L. B., Mardiana, S., Slaney, C. Y., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89455 · Cited by 325
Borea, P. A., Gessi, S., Merighi, S., & Varani, K. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.02.006 · Cited by 311
Targeting Cancer-Derived Adenosine:New Therapeutic Approaches
Young, A., Mittal, D., Stagg, J., & Smyth, M. J. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0341 · Cited by 310
Adenosine Kinase: Exploitation for Therapeutic Gain
Boison, D. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.006361 · Cited by 310
Self-citationA ketogenic diet suppresses seizures in mice through adenosine A1 receptors
Masino, S. A., Li, T., Theofilas, P., Sandau, U. S., Ruskin, D. N., Fredholm, B. B., Geiger, J. D., Aronica, E., & Boison, D. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57813 · Cited by 308
Self-citationYegutkin, G. G. (2014) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2014.953627 · Cited by 299
Self-citationVesicular and conductive mechanisms of nucleotide release
Lazarowski, E. R. (2012) · Purinergic Signalling · doi:10.1007/s11302-012-9304-9 · Cited by 297
MethHC: a database of DNA methylation and gene expression in human cancer
Huang, W.-Y., Hsu, S.-D., Huang, H.-Y., Sun, Y.-M., Chou, C.-H., Weng, S.-L., & Huang, H.-D. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1151 · Cited by 296
Epigenetic changes induced by adenosine augmentation therapy prevent epileptogenesis
Williams-Karnesky, R. L., Sandau, U. S., Lusardi, T. A., Lytle, N. K., Farrell, J. M., Pritchard, E. M., Kaplan, D. L., & Boison, D. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65636 · Cited by 266
Self-citationMedicinal chemistry of adenosine, P2Y and P2X receptors
Jacobson, K. A., & Müller, C. E. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.12.001 · Cited by 262
The purinergic receptor P2RX7 directs metabolic fitness of long-lived memory CD8+ T cells
Borges da Silva, H., Beura, L. K., Wang, H., Hanse, E. A., Gore, R., Scott, M. C., Walsh, D. A., Block, K. E., Fonseca, R., Yan, Y., et al. (2018) · Nature · doi:10.1038/s41586-018-0282-0 · Cited by 258
Bastid, J., Regairaz, A., Bonnefoy, N., Déjou, C., Giustiniani, J., Laheurte, C., Cochaud, S., Laprevotte, E., Funck-Brentano, E., Hemon, P., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0018 · Cited by 240
Buisseret, L., Pommey, S., Allard, B., Garaud, S., Bergeron, M., Cousineau, I., Ameye, L., Bareche, Y., Paesmans, M., Crown, J. P. A., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx730 · Cited by 232
The Pharmacology of CD38/NADase: An Emerging Target in Cancer and Diseases of Aging
Chini, E. N., Chini, C. C. S., Espindola Netto, J. M., de Oliveira, G. C., & van Schooten, W. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.02.001 · Cited by 227
Neonatal hepatic steatosis by disruption of the adenosine kinase gene
Boison, D., Scheurer, L., Zumsteg, V., Rülicke, T., Litynski, P., Fowler, B., Brandner, S., & Mohler, H. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092642899 · Cited by 225
Self-citationSitkovsky, M. V., Hatfield, S., Abbott, R., Belikoff, B., Lukashev, D., & Ohta, A. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0075 · Cited by 215
Equilibrative nucleoside transporters—A review
Boswell-Casteel, R. C., & Hays, F. A. (2017) · Nucleosides, Nucleotides and Nucleic Acids · doi:10.1080/15257770.2016.1210805 · Cited by 209
Regulation of the T Cell Response by CD39
Takenaka, M. C., Robson, S., & Quintana, F. J. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.04.009 · Cited by 207
T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response
Sitkovsky, M. V. (2009) · Trends in Immunology · doi:10.1016/j.it.2008.12.002 · Cited by 193
De Marchi, E., Orioli, E., Pegoraro, A., Sangaletti, S., Portararo, P., Curti, A., Colombo, M. P., Di Virgilio, F., & Adinolfi, E. (2019) · Oncogene · doi:10.1038/s41388-019-0684-y · Cited by 193
Memory of Extracellular Adenosine A2A Purinergic Receptor-mediated Signaling in Murine T Cells
Koshiba, M., Kojima, H., Huang, S., Apasov, S., & Sitkovsky, M. V. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.41.25881 · Cited by 189
CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
Morandi, F., Horenstein, A. L., Costa, F., Giuliani, N., Pistoia, V., & Malavasi, F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02722 · Cited by 176
Anti‐CD73 therapy impairs tumor angiogenesis
Allard, B., Turcotte, M., Spring, K., Pommey, S., Royal, I., & Stagg, J. (2014) · International Journal of Cancer · doi:10.1002/ijc.28456 · Cited by 171
Dominant immunosuppression of dendritic cell function by prostate‐cancer‐derived exosomes
Salimu, J., Webber, J., Gurney, M., Al‐Taei, S., Clayton, A., & Tabi, Z. (2017) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2017.1368823 · Cited by 165
Molecular Pathways: Is AMPK a Friend or a Foe in Cancer?
Hardie, D. G. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3300 · Cited by 161
Lukashev, D. E., Ohta, A., Apasov, S. G., Chen, J., & Sitkovsky, M. V. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.1.21 · Cited by 153
Shortage of Cellular ATP as a Cause of Diseases and Strategies to Enhance ATP
Johnson, T. A., Jinnah, H. A., & Kamatani, N. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00098 · Cited by 153
Bjursell, M. K., Blom, H. J., Asin-Cayuela, J., Engvall, M., Lesko, N., Balasubramaniam, S., Brandberg, G., Halldin, M., Falkenberg, M., Jakobs, C., et al. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.09.004 · Cited by 138
Spychała, J., Datta, N. S., Takabayashi, K., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.3.1232 · Cited by 130
Yegutkin, G. G., Henttinen, T. A., & Jalkanen, S. (2001) · The FASEB Journal · doi:10.1096/fj.00-0268com · Cited by 124
Self-citationFlögel, U., Burghoff, S., van Lent, P. L. E. M., Temme, S., Galbarz, L., Ding, Z., El‐Tayeb, A., Hüls, S., Bönner, F., Borg, N., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003717 · Cited by 122
Polyoxometalates—Potent and selective ecto-nucleotidase inhibitors
Lee, S.-Y., Fiene, A., Li, W., Hanck, T., Brylev, K. A., Fedorov, V. E., Lecka, J., Haider, A., Pietzsch, H., Zimmermann, H., et al. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.11.002 · Cited by 121
The hypoxia-adenosine link during inflammation
Bowser, J. L., Lee, J. W., Yuan, X., & Eltzschig, H. K. (2017) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00101.2017 · Cited by 118
Transgenic Overexpression of Adenosine Kinase Aggravates Cell Death in Ischemia
Pignataro, G., Simon, R. P., & Boison, D. (2006) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600334 · Cited by 117
Self-citationAdenosine Kinase of Arabidopsis. Kinetic Properties and Gene Expression
Moffatt, B. A., Wang, L., Allen, M. S., Stevens, Y. Y., Qin, W., Snider, J. D., & von Schwartzenberg, K. (2000) · PLANT PHYSIOLOGY · doi:10.1104/pp.124.4.1775 · Cited by 117
Controlling the Immune Suppressor: Transcription Factors and MicroRNAs Regulating CD73/NT5E
Kordaß, T., Osen, W., & Eichmüller, S. B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00813 · Cited by 116
Polyphosphate as a donor of high-energy phosphate for the synthesis of ADP and ATP
Müller, W. E. G., Wang, S., Neufurth, M., Kokkinopoulou, M., Feng, Q., Schröder, H. C., & Wang, X. (2017) · Journal of Cell Science · doi:10.1242/jcs.204941 · Cited by 112
Theofilas, P., Brar, S. K., Stewart, K.-A., Shen, H., Sandau, U. S., Poulsen, D. J., & Boison, D. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2010.02947.x · Cited by 105
Self-citationExosomes in HNSCC plasma as surrogate markers of tumour progression and immune competence
Theodoraki, M., Hoffmann, T. K., Jackson, E. K., & Whiteside, T. L. (2018) · Clinical & Experimental Immunology · doi:10.1111/cei.13157 · Cited by 105
Chen, S., Fan, J., Zhang, M., Qin, L., Dominguez, D., Long, A., Wang, G., Ma, R., Li, H., Zhang, Y., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08123-8 · Cited by 98
Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy
de Leve, S., Wirsdörfer, F., & Jendrossek, V. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00698 · Cited by 93
The role of NK cells and CD39 in the immunological control of tumor metastases
Zhang, H., Vijayan, D., Li, X.-Y., Robson, S. C., Geetha, N., Teng, M. W. L., & Smyth, M. J. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1593809 · Cited by 93
Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation
Zahnow, C. A., Topper, M. J., Stone, M. L., Stewart, T. M., Li, H., Baylin, S. B., & Casero, R. A. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.01.007 · Cited by 88
Adenosine Receptors in Wound Healing, Fibrosis and Angiogenesis
Feoktistov, I., Biaggioni, I., & Cronstein, B. N. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-89615-9_13 · Cited by 81
Armstrong, J. M., Chen, J., Schwarzschild, M. A., Apasov, S. G., Smith, P. T., Caldwell, C. C., Pearl, C. H. E. N., Figler, H., Sullivan, G. W., Steven, F. I. N. K., et al. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3540123 · Cited by 76
An Exceptionally Potent Inhibitor of Human CD73
Bowman, C. E., da Silva, R. G., Pham, A. T., & Young, S. W. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00448 · Cited by 61
Adenosine Inhibits Tumor Cell Invasion via Receptor-Independent Mechanisms
Virtanen, S. S., Kukkonen-Macchi, A., Vainio, M., Elima, K., Härkönen, P. L., Jalkanen, S., & Yegutkin, G. G. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0302-t · Cited by 55
Self-citationBhattarai, S., Pippel, J., Meyer, A. S., Freundlieb, M., Schmies, C. C., Abdelrahman, A., Fiene, A., Lee, S., Zimmermann, H., El‐Tayeb, A., et al. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201900075 · Cited by 55
Self-citationToti, K. S., Osborne, D. M., Ciancetta, A., Boison, D., & Jacobson, K. A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00689 · Cited by 53
Self-citationCD73 (Cluster of Differentiation 73) and the Differences Between Mice and Humans
Joolharzadeh, P., & Hilaire, C. S. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311579 · Cited by 48
Moeckel, D., Jeong, S. S., Sun, X., Broekman, M. J., Nguyen, A., Drosopoulos, J. H. F., Marcus, A. J., Robson, S. C., Chen, R., & Abendschein, D. R. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009246 · Cited by 38
Blockade of extracellular NM23 or its endothelial target slows breast cancer growth and metastasis
Yokdang, N., Nordmeier, S., Speirs, K., Burkin, H. R., & Buxton, I. L. O. (2015) · Integrative Cancer Science and Therapeutics · doi:10.15761/icst.1000139 · Cited by 33
Morandi, F., Marimpietri, D., Horenstein, A. L., Corrias, M. V., & Malavasi, F. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1574198 · Cited by 33
Hatfield, S. M., Halpin-Veszeleiova, K., Steingold, J., Sethuraman, J., & Sitkovsky, M. V. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-12734-3_8 · Cited by 32
Hatfield, S. M., & Sitkovsky, M. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1052934 · Cited by 31
Zeiner, J., Loukovaara, S., Losenkova, K., Zuccarini, M., Korhonen, A., Lehti, K., Kauppinen, A., Kaarniranta, K., Müller, C. E., Jalkanen, S., et al. (2019) · Journal of Molecular Medicine · doi:10.1007/s00109-018-01734-0 · Cited by 26
Self-citationIntegrative Network Modeling Approaches to Personalized Cancer Medicine
Kidd, B. A., Readhead, B., Eden, C., Parekh, S. S., & Dudley, J. T. (2015) · Personalized Medicine · doi:10.2217/pme.14.87 · Cited by 19
Cited by
The adenosine pathway in immuno-oncology
Allard, B., Allard, D., Buisseret, L., & Stagg, J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0382-2 · Cited by 586
Unveiling the mechanisms and challenges of cancer drug resistance
Khan, S. U., Fatima, K., Aisha, S., & Malik, F. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01302-1 · Cited by 417
CD39/CD73/A2AR pathway and cancer immunotherapy
Xia, C., Yin, S., To, K. K. W., & Fu, L. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01733-x · Cited by 399
Inosine is an alternative carbon source for CD8+-T-cell function under glucose restriction
Wang, T., Gnanaprakasam, J. N. R., Chen, X., Kang, S., Xu, X., Sun, H., Liu, L., Rodgers, H., Miller, E., Cassel, T. A., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0219-4 · Cited by 331
Moesta, A. K., Li, X.-Y., & Smyth, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0376-4 · Cited by 322
Metadata
- Authors
- Boison, D., & Yegutkin, G. G.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2019-12
- Volume
- 36
- Issue
- 6
- Pages
- 582-596
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2994080338
- Cited by
- 336
- References
- 91
- FWCI
- 20.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.